Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia by UMEDA, Yukihiro et al.
TITLE PAGE 
Full article title: Dual-time-point 18F-FDG PET Imaging for Diagnosis of Disease Type 
and Disease Activity in Patients with Idiopathic Interstitial Pneumonia 
Full first and last name: Yukihiro Umeda, MD1, Yoshiki Demura MD, PhD1 Takeshi 
Ishizaki MD PhD1, Shingo Ameshima MD PhD1, Isamu Miyamori MD PhD2, Yuji Saito 
MD PhD3, Tatsuro Tsuchida MD PhD4, Yasuhisa Fujibayashi PhD5, Hidehiko Okazawa 
MD PhD5 
Institutional affiliation:  
1Department of Respiratory Medicine, University of Fukui 
23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun Fukui 910-1193 Japan 
2Third Department of Internal Medicine, University of Fukui 
23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun Fukui 910-1193 Japan 
3Division of Respirology & Allergology, Department of Internal Medicine, School of 
Medicine, Fujita Health University 
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192 Japan 
4Department of Radiology, University of Fukui 
23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun Fukui 910-1193 Japan 
5Biomedical Imaging Research Center, University of Fukui 
23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun Fukui 910-1193 Japan 
Corresponding author: Yoshiki Demura, Department of Respiratory Medicine, 
University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun Fukui 
910-1193 Japan 
[e-mail address] DEM2180@aol.com  
[Telephone] +81-(0)776-61-3111  [Fax] +81-(0)776-61-8111 
    
 -  - 1
ABSTRACT 
Purpose Individual clinical courses of idiopathic interstitial pneumonia (IIP) are 
variable and difficult to predict because the pathology and disease activity are 
contingent, and chest computed tomography (CT) provides little information about 
disease activity. In this study, we applied dual-time-point 
[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET), 
commonly used for diagnosis of malignant tumors, to the differential diagnosis and 
prediction of disease progression in IIP patients. 
Methods Fifty patients with IIP, including idiopathic pulmonary fibrosis (IPF, n=21), 
nonspecific interstitial pneumonia (NSIP, n=18), and cryptogenic organizing pneumonia 
(COP, n=11), underwent 18F-FDG PET examinations at two time points: Scan 1 at 60 
min (early imaging) and Scan 2 at 180 min (delayed imaging) after 18F-FDG injection. 
The standardized uptake values (SUV) at the two points and the retention index 
(RI-SUV) calculated from them were evaluated and compared with chest CT findings, 
disease progression, and disease types. To evaluate short term disease progression, all 
patients were examined pulmonary function test every 3 months for 1 year after 
18F-FDG PET scanning. 
Results The early SUV for COP (2.47±0.74) was significantly higher than that for IPF 
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(0.99±0.29, P=0.0002) or NSIP (1.22±0.44, P=0.0025). When an early SUV cut-off 
value of 1.5 and greater was used to distinguish COP from IPF and NSIP, the sensitivity, 
specificity, and accuracy were 90.9%, 94.3%, and 93.5%, respectively. The RI-SUV for 
IPF and NSIP lesions was significantly greater in patients with deteriorated pulmonary 
function after 1-year of follow-up (progressive group, 13.0±8.9%) than in cases without 
deterioration during the 1-year observation period (stable group, -16.8±5.9%, 
P<0.0001). However, the early SUV for all IIP types provided no additional information 
of disease progression. When an RI-SUV cut-off value of 0% and greater was used to 
distinguish progressive IIPs from stable IIPs, the sensitivity, specificity, and accuracy 
were 95.5%, 100%, and 97.8%, respectively.  
Conclusion Early-SUV and RI-SUV obtained from dual-time point 18F-FDG PET are 
useful parameter for the differential diagnosis and prediction of disease progression in 
patients with IIP. 
 
Key Words: idiopathic interstitial pneumonia; dual-time point; 18F-FDG PET; disease 
activity, differential diagnosis, retention index 
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INTRODUCTION 
The idiopathic interstitial pneumonias (IIPs) are a heterogeneous group of disorders 
resulting from damage to the lung parenchyma due to varying patterns of inflammation 
and fibrosis. Idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia 
(NSIP), and cryptogenic organizing pneumonia (COP) comprise the majority of IIP 
cases. Distinguishing different types of IIP is important because COP is known to show 
a better prognosis than IPF and NSIP [1]. 
Management of patients with IIP is challenging, as many factors are involved, 
including difficulties with diagnosis and determination of disease activity. However, 
along with greater understanding of the clinical course and pathophysiology of this 
group of disorders, a recent consensus statement provided a clearer framework for both 
diagnosis and management [1]. Classification of IIPs is based on histopathological 
patterns of the disease from surgical lung biopsy specimens, as well as clinical and 
computed tomography (CT) findings. However, predicting disease progression is less 
certain in IIP. Chest CT shows changes in lung density but can give no indication of 
disease activity. Although histopathological diagnosis is related to survival in IIP 
patients, individual clinical courses are highly variable and unpredictable. Furthermore, 
thoracic surgical procedures are stressful for IIP patients [2, 3] and hazardous to repeat, 
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therefore should be avoided unless absolutely necessary, while lung segment samples 
may not accurately represent the lung as a whole [4]. 
Other noninvasive, real-time measures of lung inflammation in IIP patients, which 
can predict the disease activity, are expected. External imaging using radiolabeled 
markers of inflammatory processes has great potential for providing a noninvasive and 
repeatable test for monitoring inflammatory cell behavior. 
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) is an 
imaging modality that detects the increased uptake of glucose in areas of increased cell 
metabolism. This technique is most often applied for diagnosis of malignancy, although 
it has also been found useful for detection of benign diseases [5], such as bronchiolitis 
obliterans organizing pneumonia (BOOP) [6], IPF [7], and drug-induced pneumonitis 
[8]. 
Recently, dual-time point 18F-FDG PET has been reported as useful for not only 
diagnosing malignancy but also for assessing the disease activity of benign 
inflammatory diseases, such as tuberculoma [9]. In vitro models of activated 
inflammatory cells, such as macrophages, lymphocytes, and neutrophils, have been 
reported to have significantly increased FDG uptake [10-12]. Activation of these 
inflammatory cells causes a sustained increase in FDG accumulation over time. Thus, 
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we hypothesized that it might be possible to use dual-time point 18F-FDG PET imaging 
in patients with IIP to assess the degree of inflammation, and to provide predictive 
information of disease progression. In the present study, we evaluated the potential role 
of dual-time point 18F-FDG PET for elucidation of disease progression and 
histopathologic diagnosis (disease type) in patients with IIP. 
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MATERIALS AND METHODS 
Study Population 
We enrolled 53 consecutive patients with IIP who were treated at the University of 
Fukui Hospital between January 2004 and December 2007. Three patients were 
subsequently excluded after being diagnosed with other diseases (1 case of malignant 
disease, 2 cases of collagen vascular disease). Patients with a defined connective tissue 
disease, left ventricular failure, occupational and/or environmental exposure that 
resulted in interstitial pneumonia, or history of ingestion of a drug or agent known to 
cause pulmonary fibrosis were excluded from the study. Thus, 50 patients (21 men, 29 
women; age range, 21-84 years old; mean age ± SD, 66.2±11.6 years) were included in 
the present study. This study was approved by the Institutional Review Board of the 
hospital and written informed consent was obtained from all participating patients. All 
50 patients had untreated IIP, and were comprised of 21 with IPF, 18 with NSIP, and 11 
with COP (Table 1). None of the subjects had received steroids or immunosuppressants 
at the time of clinical sample collection. Degree of dyspnea was scored from 0 to 20, 
with a higher score indicating more severe dyspnea [13]. Pulmonary function tests 
[spirometry, measurement of lung volumes, and diffusing capacity of the lungs 
measured using carbon monoxide (DLCO)] were performed in all patients according to 
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the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines 
[14]. Arterial blood gas analysis was performed in all patients within a period of one 
week before 18F-FDG PET scan. Fiberoptic bronchoscopy was performed in all patients 
within a period of two weeks after the 18F-FDG PET scan. Thereafter, 32 patients 
underwent a surgical lung biopsy within four weeks of the 18F-FDG PET scan. 
Of the 21 patients with IPF, nine were diagnosed clinically, and pathologically 
confirmed as having a usual interstitial pneumonia (UIP) pattern on the basis of surgical 
lung biopsy results, and 12 were diagnosed as having clinical IPF according to the ATS 
clinical diagnostic criteria [15]. All 18 patients with idiopathic NSIP were diagnosed 
clinically, and pathologically confirmed fibrotic NSIP pattern on the basis of surgical 
lung biopsy results. All 11 patients with COP (i.e. idiopathic BOOP in pathology) were 
diagnosed clinically, and pathologically confirmed on the basis of surgical lung biopsy 
results (n=5), or a transbronchial lung biopsy (n=6). Pathological diagnoses were made 
according to ATS/ERS classification criteria [1]. These specimens were reviewed by at 
least two pathologists in the hospital’s pathology department without prior knowledge 
of the 18F-FDG PET results. 
 
Measurement of Serum markers 
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We assessed serum levels of Krebs von den Lungen-6 (KL-6) and surfactant proteins-D 
(SP-D) in all patients within a period of two weeks before the 18F-FDG PET scan. 
Serum KL-6 and SP-D were quantitatively determined using enzyme-linked 
immunosorbent assay [(KL-6: Sanko Junyaku; Tokyo, Japan), (SP-D: Yamasa; Chiba, 
Japan)]. Since no serum controls were available for this study, we used the normal 
range in healthy individuals provided by the manufacturer (KL-6: 94.9 to 458.2 U/mL, 
SP-D: 18.6 to 79.4 ng/mL). 
 
Thoracic CT 
Patients underwent CT scanning with a 16-detector row CT (Sensation 16; Siemens, 
Erlangen, Germany) system before 18F-FDG PET scanning. Contiguous 5.0 mm thick 
sections were initially obtained at 5.0 mm intervals throughout the thorax, followed by 
non-contrast chest high-resolution (HR) CT, which was used to obtain 2.0 mm 
cross-sectional slices at 10 mm intervals throughout the thorax. All images were 
reconstructed using a bone algorithm and obtained at window settings suitable for 
viewing lung parenchyma. 
HRCT findings for abnormal lesions were defined as follows; “honeycomb”, 
including honeycomb change, “consolidation”, including air-space consolidations, and 
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“ground grass opacities (GGO) and reticular density”, including diffuse GGO and 
reticular densities; HRCT findings with no abnormal shadows were defined as 
“normal”. 
 
18F-FDG PET 
18F-FDG PET imaging was performed using a whole-body scanner (ADVANCE; 
General Electric Medical Systems; Milwaukee, WI). All patients fasted overnight (for at 
least 12 hours) before radiotracer administration. None had insulin-dependent diabetes, 
and the serum glucose level was below 126 mg/dl in all patients immediately before the 
injection of 18F-FDG. Approximately 185 MBq of 18F-FDG (a dose commonly used for 
clinical 18F-FDG PET scans in Japan) was intravenously administered. Emission scans 
of the thorax were obtained one hour later for 20 minutes (early scan), then three hours 
later for 20 minutes (delayed scan). A transmission scan was obtained for 10 minutes 
using a standard rod source of 68Ge/68Ga for attenuation correction before each emission 
scan at the same bed position as the emission scan. For each emission scan, the patient’s 
body was carefully positioned with laser beam guidance to prevent misregistration. 
Images were viewed as transaxial slices of the thorax with a slice thickness of 4.25 mm. 
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PET Image Interpretation 
Semiquantitative analysis of 18F-FDG uptake was based on region of interest (ROI) 
analysis, which produced mean standardized uptake values (SUV) [= (local 
radioactivity concentration) / (injected dose) / (body weight)]. After PET and CT 
images were coregistered using a specific software (Body Guide; Advance Biologic, 
Toronto, Canada), circular ROIs with a fixed size of 30 mm in diameter were drawn on 
the CT images in the anterior, lateral, and posterior sites of the bilateral lungs (Fig. 1) at 
three representative slice levels; the upper lung field, considered to be at the level of the 
aortic arch; the middle lung field, considered to be at the level of tracheal bifurcation; 
and the lower lung field, considered to be above the level of the diaphragm. The ROIs 
were placed by two experienced radiologists. For comparison of images acquired at 1 
and 3 hours, the same ROIs were applied to both early and delayed PET images of the 
same CT level. The retention index (RI-SUV) was calculated from the SUV levels of 
one hour (early SUV) and three hours (delayed SUV) using the following equation:  
RI-SUV (%) = (delayed SUV – early SUV) × 100/ early SUV.  
For analysis of 18F-FDG uptake in IIP lesions, SUV levels of each lesion, assessed by 
the ROI method, were classified according to CT findings. The early SUV and RI-SUV 
for lesions were averaged for ROIs of lesions that had an abnormal shadow (honeycomb, 
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consolidation, GGO and reticular density) on corresponding HRCT images. The early 
SUV and RI-SUV for normal lung fields were averaged among all ROIs without any 
abnormal shadow on corresponding HRCT images. The averaged early SUVs and 
RI-SUVs of the abnormal shadows, as well as normal lung, were compared between 
diseases. 
 
Clinical Reevaluation 
To evaluate short-term disease progression of IIP, we examined all patients at least 
every 3 months for 1 year after 18F-FDG PET scanning to determine whether their 
condition with regard to the disease had improved or remained the same (stable IIP) or 
deteriorated (progressive IIP). Patients were not given any steroid or other 
immunosuppressant therapy. Progressive IIP was defined according to ATS criteria [14], 
and included patients who had evidence of deterioration within 12 months after 
18F-FDG PET scanning in regard to pulmonary function in two or more of the following 
categories: a 10% decrease in total lung capacity or vital capacity (or ≥200-mL change), 
a 15% decrease in single-breath DLCO (or at least ≥3-ml/min/mmHg change), worsening 
(greater fall) of O2 saturation (≥4 percentage point decrease in the measured saturation), 
or a rise in alveolar-arterial oxygen pressure difference (AaDO2) at rest (≥4 mmHg 
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increase from the previous measurement). Patients who did not show deterioration over 
the 1-year observation period were defined as having stable IIP. 
 
Statistical Analysis 
All values express the mean ± SD. Differences in SUV and RI-SUV level and clinical 
data among multiple groups were determined with non-parametric Kruskal-Wallis test 
and Steel-Dwass test to assess between-group comparisons. For all analyses, P values 
less than 0.05 were considered to be statistically significant. 
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RESULTS 
Subject and Clinical Characteristics 
Patient characteristics are shown in Table 1. Of the 50 patients with IIP, 25 showed 
deterioration during the 1-year observation period (progressive IIP 50.0%). These 25 
were comprised of 8 of the 21 patients with IPF (progressive IPF 38.1%), 9 of the 18 
with NSIP (progressive NSIP 50.0%), and 8 of the 11 with COP (progressive COP 
72.7%). 
Table 2 outlines dyspnea score, serum markers, arterial blood gas analysis, and 
pulmonary function data of study participants. The KL-6 levels of patients with IPF and 
NSIP were higher than those of patients with COP, whereas there was no difference in 
SP-D. The resting arterial partial pressure of oxygen (PaO2) of patients with IPF and 
NSIP was higher than that of patients with COP. There were no differences between 
disease types in dyspnea score, vital capacity (VC), and DLCO. 
 
HRCT findings 
Table 2 also shows the findings of HRCT. About 90% of patients with IPF had a 
dominant honeycombing pattern with some degree of GGO or reticular density. For 
NSIP, all patients had GGO and reticular density as the dominant pattern and about half 
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of the patients had consolidation. Only three patients had honeycombing. About 90% of 
patients with COP had consolidation and/or GGO. 
 
Period between 18F-FDG PET scan and Initiation of Therapy 
Of 25 patients with progressive IIP, 19 (three of eight progressive IPF, eight of nine 
progressive NSIP, and all eight progressive COP) were treated during 1-year follow-up. 
The median period between PET scan and initiation of therapy was 96 days (range, 
90-150 days) for IPF patients, 49.5 days (range, 30-353 days) for NSIP, and 34.5 days 
(range, 20-40 days) for COP. 
 
18F-FDG PET in IIP 
Figure 2A shows the distribution of early SUV levels for lung lesions in patients 
with IIPs. Table 3 shows the mean early SUV level in patients with IIP according to CT 
findings. The early SUV of lung lesions, defined as abnormal shadows on CT images, 
was significantly higher than that in normal lung areas (normal) in all three IIP groups. 
The early SUV of lung lesions in COP (2.47±0.74) was significantly higher than that in 
IPF (0.99±0.29, P = 0.0002, analyzed by the Steel-Dwass test) or NSIP (1.22±0.44, P = 
0.0025). Receiver operating characteristic (ROC) curve analysis determined that the 
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most suitable cut-off value for early SUV at lung lesions was 1.5 to distinguish COP 
from the IPF and NSIP groups. When this threshold for early SUV was used to diagnose 
COP, sensitivity, specificity, and accuracy of 18F-FDG PET were 90.9%, 94.3%, and 
93.5%, respectively. In addition, when the analysis was limited to surgically confirmed 
cases, the early SUV of lung lesions in COP (2.66±0.82, n=5) was significantly higher 
than that in IPF (0.94±0.25, P = 0.0072, analyzed by the Steel-Dwass test, n=9) or NSIP 
(1.22±0.44, P = 0.0036, n=18). In surgically confirmed cases, when early SUV of 1.5 
was used to diagnose COP, sensitivity, specificity, and accuracy of 18F-FDG PET were 
100%, 96.3%, and 96.9%, respectively. 
Table 4 shows the comparison of early SUV in each lesion type according to chest 
HRCT findings. In patients with IPF, NSIP and COP, the early SUV level of 
honeycomb and consolidation on corresponding HRCT images was significantly higher 
than that of GGO and reticular density. However, there was no difference between 
honeycomb and consolidation in patients with IPF and NSIP. 
 
Disease Progression and Dual-time point 18F-FDG PET 
We also determined the relationship between short term disease progression and 
dual-time point 18F-FDG PET findings in patients with IIP. There was no significant 
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difference in early SUV level between patients with progressive IIPs and stable ones 
(Table 5). In contrast, the RI-SUVs were significantly higher in patients with 
progressive IPF and NSIP (13.0±8.9%) compared to patients with stable IPF and NSIP 
(-16.8±5.9%, P < 0.0001, analyzed by the Steel-Dwass test). The progressive COP 
group (19.8±6.0%) had a tendency to increase the RI-SUVs compared to patients with 
stable COP (-16.6±13.3%, P = 0.056). Figure 2B shows the distribution of RI-SUV 
levels for lung lesions in patients with IIPs. ROC curve analysis indicated that the most 
suitable cut-off value for RI-SUV at lung lesions was 0% to distinguish the progressive 
from stable IIP group. When using a RI-SUV threshold of 0% to differentiate 
progressive IIP, sensitivity, specificity, and accuracy were 95.5%, 100%, and 97.8%, 
respectively. In addition, when the analysis was limited to surgically confirmed cases, 
the RI-SUVs were significantly higher in patients with progressive IPF and NSIP 
(13.1±10.3%, n=12) compared to patients with stable IPF and NSIP (-16.4±6.9%, P = 
0.0001, analyzed by the Steel-Dwass test, n=15). There was no significant difference 
between progressive COP group (19.2±3.6%, n=3) and stable COP (-20.9%, P = 0.26, 
n=2). In surgically confirmed cases, when using a RI-SUV threshold of 0% to 
differentiate progressive IIP, sensitivity, specificity, and accuracy were 93.3%, 100%, 
and 96.9%, respectively. 
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Representative 18F-FDG PET images used for evaluation of disease progression in 
pathologically diagnosed fibrotic NSIP cases are shown in Figures 3 and 4. One patient 
with NSIP who had evidence of deterioration in pulmonary function three months after 
the 18F-FDG PET scan (progressive NSIP, Figure 3) had a positive RI-SUV value 
(24.3%), while a patient with NSIP who did not show deterioration of pulmonary 
function at one year after 18F-FDG PET scanning (stable NSIP, Figure 4) had a negative 
RI-SUV value (-22.0%). 
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DISCUSSION 
In the present study of 50 patients with IIP, we found that the early SUV (cut-off: 
1.5) in COP was significantly higher than that in IPF and NSIP with reasonable 
sensitivity and specificity, although no significant difference between IPF and NSIP was 
observed. On the other hand, a positive value of RI-SUV (cut-off: 0%) predicts the 
deterioration of pulmonary function within a 1-year observation period in patients with 
IIP. However, early SUV was not a significant predictor of disease progression. 
Regarding with image diagnosis of IIPs, the early SUV level of 18F-FDG PET could 
be useful for distinguishing COP from IPF and NSIP. According to the ATS/ERS 
consensus classification of IIPs [1], the main histopathologic feature of COP is a patchy 
process characterized primarily by organizing pneumonia involving variable numbers of 
inflammatory cells, such as lymphocytes, macrophages, and neutrophils, with a lower 
degree of interstitial fibrosis, as compared to IPF and NSIP. Nagai et al. noted that 
increased cell recovery and percentage of lymphocytes in BAL fluid were found in 
patients with COP, compared to those with IPF [16]. These findings suggest that the 
degree of inflammatory cell infiltrates has an effect on early SUV in IIP. 
Our results also indicate that RI-SUV is useful for determining disease activity as a 
predictor of disease progression. Although hiatopathological diagnosis is related to 
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response to treatment as well as survival in IIP patients [16], a recent report showing a 
high mortality rate (21.7%) for patients with IPF after surgical lung biopsy has raised 
safety concerns and initiated debate regarding surgical lung biopsy procedures for IPF 
patients [3]. Furthermore, the natural histories of IPF and NSIP are not well defined. 
Although the course of IPF is typically described as a relentless decline in respiratory 
function, individual courses are highly variable and some patients remain stable for 
extended periods of time without treatment [17]. On the other hand, the survival rates of 
patients with NSIP vary considerably among studies. Travis et al. reported a 5-year 
survival rate of 90% for NSIP [18], whereas Nicholson et al. found it to be only 45% 
[19]. This variability and considerable overlap in patient survival on the basis of these 
pathologic patterns [16, 18, 19] indicate a need to define other non-invasive prognostic 
parameters. 
Recently, several studies have shown that serial changes in dyspnea and lung 
function are predictive markers of survival in IIP [20-23]. In particular, deterioration in 
forced vital capacity and DLCO during the initial 6 to12 months is a stronger predictor of 
survival than pathological diagnosis in IPF and NSIP patients [22, 23]. However, these 
serial physiologic parameters cannot be assessed at the time of initial presentation. 
Since RI-SUV could predict the deterioration of pulmonary function after 12 months of 
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follow-up examinations, it has potential as a predictor of survival in IPF and NSIP 
patients at the time of diagnosis. 
Tumoral FDG uptake does not reach its maximum value until 5 hours after 
administration [24], whereas benign inflammatory lesions and physiologic FDG uptake 
lesions show a stable pattern or a slight decline [25]. However, a recent report showed 
that the increase in 18F-FDG uptake between early and delayed PET images is a 
predictor for activity of pulmonary tuberculoma [9]. In addition, activation of 
inflammatory cells causes a sustained increase in FDG accumulation over time [10-12]. 
These findings suggest that inflammatory cell activity is associated with sustained FDG 
uptake (positive RI-SUV value) in progressive IIP lung. 
Based on the data presented, it might be possible to use dual-time point 18F-FDG 
PET imaging to classify IIPs into four groups, and for management of IIPs (Fig. 5), as 
follows: 1) High early SUV level (> 1.5) and positive RI-SUV (> 0%) correspond to 
progressive COP patients. Since it is predicted that patients will have deterioration of 
pulmonary function in the short term and good response to corticosteroid therapy, 
corticosteroid therapy is required; 2) High early SUV level (> 1.5) and negative 
RI-SUV (< 0%) could correspond to stable COP patients, and patients could be 
expected to show improvement within a 1-year observation period; 3) Low early SUV 
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level (< 1.5) and positive RI-SUV (> 0%) are progressive IPF and NSIP patients. Since 
it is predicted that patients will have deterioration of pulmonary function within 12 
months and poor to moderate response to corticosteroid therapy, other treatment options 
may be required (e.g. immunosuppressants); and 4) Low early SUV level (< 1.5) and 
negative RI-SUV (< 0%) are stable IPF and NSIP patients. Since it is predicted that 
patients will not show deterioration of pulmonary function within 12 months and 
usually have poor response to corticosteroid treatment, immediate corticosteroid therapy 
may not be required. 
In conclusion, this first and preliminary study indicates that dual-time point 
18F-FDG PET can provide non-invasive information for characterization of IIP as well 
as a prediction of disease progression and responsiveness to treatment with 
corticosteroids at the time of initial presentation. In the future, it will be necessary to 
clarify the usefulness of dual-time point 18F-FDG PET imaging using a prognostic 
marker of IIPs, especially of IPF and NSIP, with a larger series of patients and longer 
follow-up period. 
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Table 1 Patient characteristics 
  Number of cases   
(1) Patients 50   
Sex (M/F) 21/29   
Mean age  
(years, mean±SD) 
66.2±11.6   
Age range (years) 21-84   
     
(2) Diagnosis Number of cases Progressive IIP Stable IIP 
IPF 21 8 13 
NSIP 18 9 9 
COP 11 8 3 
Total 50 25 25 
 
Abbreviations: IIP = idiopathic interstitial pneumonia; IPF = idiopathic pulmonary 
fibrosis; NSIP = nonspecific interstitial pneumonia; COP = cryptogenic organizing 
pneumonia. 
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Table 2 Clinical feature, serum markers, selected pulmonary function indices, and 
radiologic features of study participants 
 IPF (n=21) NSIP (n=18) COP (n=11) 
Dyspnea score (0-20) 8.1±2.7 7.6±2.5 8.0±3.3 
KL-6 (U/mL) 828±652† 1363±917† 329±98 
SP-D (ng/mL) 156±108 253±234 165±132 
Resting PaO2 (mmHg) 82.9±10.5* 76.7±8.1† 67.3±9.1 
VC, % predicted 83.2±27.0 79.9±21.4 77.6±18.8 
DLCO, % predicted 56.4±21.2 53.7±16.5 60.2±23.9 
HRCT findings (n)    
Honeycomb 19/21 3/18  
Consolidation 7/21 10/18 10/11 
GGO and reticular density 21/21 18/18 10/11 
Values express the mean±SD. 
The Kruskal-Wallis test analyzed multiple group comparisons and Steel-Dwass test 
assessed between-group comparisons. 
* P < 0.01, versus COP. 
† P < 0.05, versus COP. 
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Table 3 Comparison of early SUV in IIP according to chest CT findings on an 
individual patient basis 
CT findings IPF NSIP COP 
Abnormal shadow 0.99±0.29† 1.22±0.44† 2.47±0.74 
Normal 0.57±0.12 0.67±0.18 0.70±0.25 
Values express the mean±SD. 
The Kruskal-Wallis test analyzed overall group comparisons and Steel-Dwass test 
assessed between-group comparisons. 
* P < 0.01. 
† P < 0.01, versus COP.   
Abbreviations: IIP = idiopathic interstitial pneumonia; CT = computed tomography; IPF 
= idiopathic pulmonary fibrosis; NSIP = nonspecific interstitial pneumonia; COP = 
cryptogenic organizing pneumonia. 
 
* * * 
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Table 4 Comparison of early SUV in each lesion type according to chest HRCT 
findings 
HRCT findings IPF NSIP COP 
Honeycomb 1.32±0.47* 1.90±0.48†  
Consolidation 1.39±0.51† 1.72±0.62* 3.67±1.25* 
GGO and reticular density 0.82±0.23 1.15±0.38 1.87±0.56 
Values express the mean±SD. 
The Kruskal-Wallis test analyzed multiple group comparisons and statistical 
significance of difference among three groups of HRCT finding was calculated using 
Steel-Dwass test. 
* P < 0.01, versus GGO. 
† P < 0.05, versus GGO. 
ns ns  
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Table 5 Comparison of early SUV and RI-SUV between NSIP, IPF group and COP 
 NSIP and IPF COP 
 
Progressive 
(n=17) 
Stable 
(n=22) 
Progressive 
(n=8) 
Stable  
(n=3) 
Early SUV 1.21±0.50* 1.01±0.20† 2.51±0.76 2.36±0.51 
RI-SUV (%) 13.0±8.9‡ -16.8±5.9 19.8±6.0§ -16.6±13.3 
Values express the mean±SD. 
The Kruskal-Wallis test analyzed multiple group comparisons and Steel-Dwass test 
assessed between-group comparisons. 
* P < 0.01, versus progressive COP.  
† P < 0.05, versus stable COP. 
‡ P < 0.0001, versus stable NSIP and IPF. 
§ P = 0.056, versus stable COP. 
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Figure Legends 
Fig. 1 Six circular ROIs (30 mm in diameter) drawn on bilateral lungs at three 
representative slice levels with reference to individual CT images 
ROIs for normal lung (broken line) and consolidation (solid line) were defined by 
corresponding CT images. 
 
Fig. 2 Box plot of early SUV (A) and retention index (RI-SUV) (B) in patients with 
IPF (progressive, n = 8; stable, n = 13), NSIP (progressive, n = 9; stable, n = 9), and 
COP (progressive, n = 8; stable, n = 3)  
(A) Receiver operating characteristic (ROC) curve analysis determined that the most 
suitable cut-off value for early SUV at lung lesions was 1.5 (broken line) to distinguish 
COP from the IPF and NSIP groups. (B) ROC curve analysis indicated that the most 
suitable cut-off value for RI-SUV at lung lesions was 0% (broken line) to distinguish 
the progressive from stable IIP group. Box plots show the 10th, 25th, 75th, and 90th 
percentiles, as well as the median. 
 
Fig. 3 A 70-year-old woman with pathologically diagnosed NSIP  
Deterioration of pulmonary function was seen at 3 months after 18F-FDG PET scanning 
    
 -  - 34
and she died 3 years after the initial diagnosis because of respiratory dysfunction. (A) 
Chest HRCT showing ground-glass opacities and reticular shadows in both lung fields. 
(B) Transaxial 18F-FDG PET (early imaging) showing 18F-FDG accumulation in lesions 
with abnormal shadows on corresponding CT images. (C) 18F-FDG PET (delayed 
imaging) showing increased 18F-FDG accumulation compared to early imaging 
(RI-SUV = 24.3%). 
 
Fig. 4 A 73-year-old woman with pathologically diagnosed NSIP  
No deterioration of pulmonary function was seen 1 year after 18F-FDG PET scanning. 
(A) Chest HRCT showing ground-glass opacities and reticular shadows in both lung 
fields. (B) Transaxial 18F-FDG PET (early imaging) showing 18F-FDG accumulation in 
lesions with abnormal shadows on corresponding CT images. (C) 18F-FDG PET 
(delayed imaging) showing decreased 18F-FDG accumulation compared to early 
imaging (RI-SUV = -22.0%). 
 
Fig. 5 Schematic drawing of proposed diagnosis of disease type and activity with 
dual-time point 18F-FDG PET  
It might be possible to use dual-time point 18F-FDG PET to classify IIPs into four 
    
 -  - 35
groups. The early SUV (cut-off level: 1.5) can distinguish COP from IPF and NSIP. On 
the other hand, the RI-SUV (cut-off level: 0%) can predict short term (1 year) disease 
progression, with a positive RI-SUV value predicting deterioration of pulmonary 
function within a 1-year observation period and a negative RI-SUV value predicting a 
spontaneous remission or no evidence of deterioration of pulmonary function within a 
1-year observation period. 
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Figure1 
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Figure3 
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Figure4 
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